IL158440A0 - Vaccines including as an adjuvant type 1 ifn and processes related thereto - Google Patents
Vaccines including as an adjuvant type 1 ifn and processes related theretoInfo
- Publication number
- IL158440A0 IL158440A0 IL15844002A IL15844002A IL158440A0 IL 158440 A0 IL158440 A0 IL 158440A0 IL 15844002 A IL15844002 A IL 15844002A IL 15844002 A IL15844002 A IL 15844002A IL 158440 A0 IL158440 A0 IL 158440A0
- Authority
- IL
- Israel
- Prior art keywords
- ifn
- processes related
- vaccines including
- adjuvant type
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01830261A EP1250933A1 (en) | 2001-04-17 | 2001-04-17 | Vaccines including as an adjuvant high dose type I IFN |
| PCT/IT2002/000236 WO2002083170A1 (en) | 2001-04-17 | 2002-04-16 | Vaccines including as an adjuvant type 1 ifn and processes related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158440A0 true IL158440A0 (en) | 2004-05-12 |
Family
ID=8184491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15844002A IL158440A0 (en) | 2001-04-17 | 2002-04-16 | Vaccines including as an adjuvant type 1 ifn and processes related thereto |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040146485A1 (zh) |
| EP (2) | EP1250933A1 (zh) |
| JP (1) | JP2004533431A (zh) |
| KR (1) | KR20040022423A (zh) |
| CN (1) | CN100509056C (zh) |
| AU (1) | AU2002309245B2 (zh) |
| BR (1) | BR0208980A (zh) |
| CA (1) | CA2443912A1 (zh) |
| EA (1) | EA006211B1 (zh) |
| IL (1) | IL158440A0 (zh) |
| MX (1) | MXPA03009515A (zh) |
| NZ (1) | NZ529562A (zh) |
| WO (1) | WO2002083170A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040223949A1 (en) * | 2002-10-22 | 2004-11-11 | Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. | Vaccines using high-dose cytokines |
| GB0423681D0 (en) * | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
| WO2006123164A2 (en) * | 2005-05-19 | 2006-11-23 | The Edward Jenner Institute For Vaccine Research | Lps-binding and bactericidal cytokines and interferons |
| AU2010232915A1 (en) | 2009-04-03 | 2011-10-20 | Duke University | Formulation for inducing broadly reactive neutralizing anti-HIV antibodies |
| US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
| AU2016259020B2 (en) * | 2015-05-07 | 2021-12-09 | Baylor College Of Medicine | Dendritic cell immunotherapy |
| CN107233568A (zh) * | 2017-06-20 | 2017-10-10 | 上海赛伦生物技术股份有限公司 | 一种免疫马用的免疫佐剂 |
| WO2022251406A1 (en) * | 2021-05-28 | 2022-12-01 | The Regents Of The University Of Michigan | Combined agonist adjuvant for coronavirus vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820514A (en) * | 1985-12-30 | 1989-04-11 | Texas A&M University System | Low dosage of interferon to enhance vaccine efficiency |
| US6660258B1 (en) * | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| FR2769505B1 (fr) * | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
| TW586944B (en) * | 1998-05-29 | 2004-05-11 | Sumitomo Pharma | Controlled release agent having a multi-layer structure |
| ATE320266T1 (de) * | 1999-07-22 | 2006-04-15 | Dainippon Sumitomo Pharma Co | Induktion von antigen-spezifischen t-zellen durch interferon |
-
2001
- 2001-04-17 EP EP01830261A patent/EP1250933A1/en not_active Withdrawn
-
2002
- 2002-04-16 KR KR10-2003-7013660A patent/KR20040022423A/ko not_active Application Discontinuation
- 2002-04-16 CA CA002443912A patent/CA2443912A1/en not_active Abandoned
- 2002-04-16 IL IL15844002A patent/IL158440A0/xx unknown
- 2002-04-16 NZ NZ529562A patent/NZ529562A/en unknown
- 2002-04-16 AU AU2002309245A patent/AU2002309245B2/en not_active Expired - Fee Related
- 2002-04-16 BR BR0208980-7A patent/BR0208980A/pt not_active IP Right Cessation
- 2002-04-16 MX MXPA03009515A patent/MXPA03009515A/es not_active Application Discontinuation
- 2002-04-16 EA EA200301125A patent/EA006211B1/ru not_active IP Right Cessation
- 2002-04-16 JP JP2002580971A patent/JP2004533431A/ja active Pending
- 2002-04-16 CN CNB02810045XA patent/CN100509056C/zh not_active Expired - Fee Related
- 2002-04-16 WO PCT/IT2002/000236 patent/WO2002083170A1/en active IP Right Grant
- 2002-04-16 US US10/475,237 patent/US20040146485A1/en not_active Abandoned
- 2002-04-16 EP EP02735963A patent/EP1381391A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN100509056C (zh) | 2009-07-08 |
| EA200301125A1 (ru) | 2004-04-29 |
| KR20040022423A (ko) | 2004-03-12 |
| EP1250933A1 (en) | 2002-10-23 |
| WO2002083170A1 (en) | 2002-10-24 |
| BR0208980A (pt) | 2004-12-28 |
| CA2443912A1 (en) | 2002-10-24 |
| EP1381391A1 (en) | 2004-01-21 |
| AU2002309245B2 (en) | 2008-03-13 |
| MXPA03009515A (es) | 2004-12-06 |
| NZ529562A (en) | 2005-09-30 |
| CN1522154A (zh) | 2004-08-18 |
| JP2004533431A (ja) | 2004-11-04 |
| EA006211B1 (ru) | 2005-10-27 |
| US20040146485A1 (en) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227966A0 (en) | Vaccination kit | |
| GB0103170D0 (en) | Vaccine composition | |
| GB0103171D0 (en) | Vaccine composition | |
| HUP0402259A3 (en) | Vaccines | |
| HUP0402471A3 (en) | Vaccine | |
| EP1455793A4 (en) | ANTI-DIABETAL FORMULATION AND METHOD | |
| GB0112699D0 (en) | Process for the preparation of prostglandins and analogues thereof | |
| GB0407935D0 (en) | Vaccine | |
| HUP0303372A3 (en) | Vaccine | |
| EP1423141A4 (en) | VACCINE | |
| EP1549135A4 (en) | VACCINE AND ADJUVANT COMPOSITIONS | |
| GB0121171D0 (en) | Vaccine | |
| IL157609A0 (en) | A vaccine composition and method of using the same | |
| EP1370240A4 (en) | NEUROPROTECTOR FORMULATIONS AND METHOD | |
| AU2003259374A8 (en) | Vaccine comprising il-13 and an adjuvant | |
| IL158440A0 (en) | Vaccines including as an adjuvant type 1 ifn and processes related thereto | |
| IL158124A0 (en) | Leishmania vaccines | |
| GB0105238D0 (en) | Vaccines | |
| GB0113552D0 (en) | Vaccines | |
| GB0106589D0 (en) | Vaccine | |
| GB0130823D0 (en) | Vaccine | |
| GB0115496D0 (en) | Vaccine | |
| GB0124137D0 (en) | Vaccine | |
| GB0128312D0 (en) | Vaccine | |
| GB0103867D0 (en) | Vaccine |